Taipei City Hospital

Consent Form for Research Project Subjects

Project No.:

Project Title: Antidepressant Prescribing Patterns and Clinical Correlations in Asia: A Cross-sectional Multinational Multicenter Study (REAP-AD3).

Name of Research Institution:

Research Budget:

Principle Investigator:

Contact Tel:

Project implementation period (from the expected start to the submission of the final report): From March 1, 2023 to June 31, 2023

Name of subject: Gender: Age:

Medical record number:

Contact number:

mailing address:

1. Purpose of the study:

Research on Asian Psychotropic prescription study (REAP) is a consortium consisting of psychiatrists, pharmacologists, epidemiologists, and researchers in Asia. Since 2001, REAP has completed four surveys on antipsychotics (schizophrenia) prescription patterns, two on antidepressants (major depression), and one on mood stabilizers (affective disorder). The cumulative research has involved more than 600 psychiatrists, more than 100 psychiatric medical units, and 13,500 patients in the data analysis of REAP. So far, more than 90 research reports have been published in international journals. Major depressive disorder is a common mental disorder that affects approximately 280 million people worldwide. World Health Organization research data have shown that the number of global major depressive illnesses increased from 172 million in 1990 to 258 million in 2017, an increase of nearly 50% during this period. Given the rising incidence of major depressive disorder, it is not surprising that prescription consumption of antidepressants is increasing year by year. With the development of some new antidepressants with

different pharmacological mechanisms, clinical prescriptions and treatment models are gradually used in other mental disorders besides major depression. At present, many western countries have conducted relevant research on this issue. In Asia, we hope to understand the changes in the use of antidepressants in these areas through this study. The results of this study can provide clinicians the information on antidepressant prescription patterns in various countries, and references for policy formulation by competent authorities. Furthermore, as the COVID-19 pandemic is a socially important issue in every country, and Hikikomori, a pathological condition of social withdrawal is getting popular in modern society, related information on study subjects will also be collected.

2. Study Procedure:

After you agree to take part in the study, the investigator will record the antidepressants you take, then record your basic demographic information such as date of birth day, gender, height, and weight. You will also be asked about your depression-related symptoms and comorbidities. Then you need to fill in four questionnaires, including 1. Nine questions of the Patient Health Questionnaire-9 (PHQ-9); 2. Seven questions of the Generalized Anxiety Disorder 7 (GAD-7); Seven questions of the Fear of COVID-19 Scale and experiences of COVID-19; and Twenty-five questions of the One month version of Hikikomori Questionnaire (HQ-25M) according to your current situation. The total time required is about 30-40 minutes.

3. Risk from the study:

Participation in this study will have no physiological consequences. A clinical assessment of your treatment experience or related symptoms that may trigger tension or cause you unpleasant memories. If the interviewee (you) still has concerns, questions or related issues in this regard, please respond to the researcher, and we will provide necessary assistance.

4. Benefits from the study:

To establish the drug dosage, diagnosis, and related mental symptoms of antidepressants used by Asian patients with mental illness, as a reference for clinicians to prescribe drugs in the future. Also the influences of COVID-19 in psychiatric patients will be explored.

5. Complication:

No additional risks compared to standard management protocol.

6. Compensation:

The investigator will offer you a coupon valued 3 US dollars.

7. Confidentiality:

The investigator will keep your personal information and scales in a confidential and safe place. Your scale results will be logged in the computer server anonymously (removing your name and personal information), and finally these data together will be analyzed with results from other Asian countries.

8. Rights of the participants:

Right to not participate in the study. Right to withdrawal at any time from the study.

9. Alternatives to participation in the study:

Non-participation will not make any difference to management protocol of patients. Patients are free to not participate without any repercussions.

Consent

1. I have been explained the nature of the study by Investigator and had the opportunity to ask questions.

2. I understand that my participation in the study is voluntary and that I am free to withdrawal at any time, without giving any reason and without my medical care or legal rights being affected.

3. I agree not to restrict the use of any data or results that arise from this study provided such use is only for scientific purposes.

4. I agree to take part in the above study.

Signature of the Subject:

_____

Date: (DD/Mon/Year)_____

Investigator's statement:

I, the undersigned have explained to the patient in a language she/he understands the procedures to be followed in the study and risks and benefits.

Signature of the Investigator:

_____

Date: (DD/Mon/Year)_____